Paul Tudor Jones's RXRX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 0 shares of Recursion Pharmaceuticals, Inc. (RXRX) worth $0, representing 0.00% of the portfolio. First purchased in 2022-Q1, this short-term holding has been held for 6 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in RXRX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 265,296 shares. Largest reduction occurred in Q2 2026, reducing 265,296 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Recursion Pharmaceuticals (RXRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Recursion Pharmaceuticals (RXRX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -265,296 | Sold Out | 0 | $0.00 |
| Q1 2026 | +265,296 | New Buy | 265,296 | $3.07 |
| Q4 2023 | -21,544 | Sold Out | 0 | $0.00 |
| Q3 2023 | +21,544 | New Buy | 21,544 | $7.65 |
| Q2 2022 | -11,914 | Sold Out | 0 | $0.00 |
| Q1 2022 | +11,914 | New Buy | 11,914 | $7.13 |
Paul Tudor Jones's Recursion Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Recursion Pharmaceuticals, Inc. (RXRX) in Q1 2022, acquiring 11,914 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Recursion Pharmaceuticals, Inc. (RXRX) for 6 quarters since Q1 2022.
Paul Tudor Jones's largest addition to Recursion Pharmaceuticals, Inc. (RXRX) was in Q1 2026, adding 265,296 shares worth $814,459.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 0 shares of Recursion Pharmaceuticals, Inc. (RXRX), valued at approximately $0.
As of the Q2 2026 filing, Recursion Pharmaceuticals, Inc. (RXRX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Recursion Pharmaceuticals, Inc. (RXRX) was 265,296 shares, as reported at the end of Q1 2026.